Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.63 USD | -4.12% | -3.55% | -12.37% |
Apr. 22 | Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder | MT |
Apr. 12 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.61M |
---|---|---|---|---|---|
Net income 2024 * | -6M | Net income 2025 * | -9M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.82
x | P/E ratio 2025 * |
-1.02
x | Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.96% |
1 day | -4.12% | ||
1 week | -3.55% | ||
Current month | -4.12% | ||
1 month | +40.52% | ||
3 months | +35.83% | ||
6 months | -24.54% | ||
Current year | -12.37% |
Managers | Title | Age | Since |
---|---|---|---|
Bankole Johnson
FOU | Founder | 64 | 10-10-31 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Joseph Truluck
DFI | Director of Finance/CFO | 46 | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jack W. Reich
LAW | General Counsel | - | 20-05-18 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Tony Goodman
COO | Chief Operating Officer | 60 | 17-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 1.63 | -4.12% | 224,282 |
24-05-03 | 1.7 | -5.03% | 107,846 |
24-05-02 | 1.79 | +1.70% | 245,299 |
24-05-01 | 1.76 | +3.53% | 129,553 |
24-04-30 | 1.7 | +0.59% | 236,708 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.37% | 6.89M | |
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |
- Stock Market
- Equities
- ADIL Stock